$1.420
+0.173 (+12.16%)At close
RENB News
RENB Events
Lunai Bioworks Reveals Preliminary Findings from AI-Driven Platform
Lunai Bioworks announced early results from its AI-based platform designed to identify compounds that interact with acetylcholinesterase, the same molecular target affected by nerve agents. "This research brings us closer to a future where proactive, AI-powered screening can detect and evaluate neurotoxic compounds before they become threats," said David Weinstein, CEO. "Our vision is to use in vivo systems like zebrafish, combined with predictive AI, to rapidly identify neurotoxic threats and screen for countermeasures, and leverage our AI models to help safeguard against the creation of new neurotoxins." Using a combination of chemical feature analysis and machine learning classifiers, Lunai's platform demonstrated an ability to differentiate active AChE inhibitors from inactive compounds with high accuracy. The work builds on models trained using the company's in-house neuroactive compound screening data, as well as public sources, and applies predictive modeling to identify chemical signatures associated with AChE inhibition. Compounds with previously unidentified, potential neurotoxic activity have been identified for follow-up and validation. In future phases, the company plans to integrate its behavioral zebrafish profiling platform to observe real-time physiological effects of predicted inhibitors, helping prioritize candidate compounds for further development as potential countermeasures.
Lunai Bioworks Introduces Fresh Corporate Branding
Lunai Bioworks announced the formal adoption of its new corporate identity, reflecting a sharpened strategic focus and a streamlined capital structure following a 10:1 reverse stock split. The rebranding from Renovaro Inc. to Lunai Bioworks marks a pivotal evolution in the company's mission: to capture biological signals at scale, decode them using AI, and validate them quickly in model systems. The new identity underscores Lunai's dual commitment to therapeutic innovation and biodefense preparedness, positioning the company as a category leader at the intersection of artificial intelligence, healthcare, and global security. Effective September 30, 2025, Lunai's common stock will trade under the new ticker symbol "LNAI" on the Nasdaq Capital Market. The reverse stock split reduces outstanding shares from approximately 231.8 million to 23.2 million, enhancing capital efficiency and aligning with Nasdaq's minimum bid price requirements.
Lunai Bioworks Progresses in Preclinical Program for Biomarker Discovery in Parkinson's Disease
Lunai Bioworks announced advancement of its biomarker discovery preclinical program in Parkinson's Disease. The initiative leverages BioSymetrics' proprietary Augusta Platform to unlock novel treatment pathways in one of the world's fastest-growing neurological markets. The company is actively positioning the program for strategic partnership with pharmaceutical collaborators. BioSymetrics' approach centers on phenogrouping, identifying distinct patient subtypes using its Phenograph knowledge graph and machine learning engine. This enables the company to stratify patients with greater precision, uncover hidden disease mechanisms, and match subgroups with targeted therapeutic hypotheses. The strategy was recently spotlighted in a Michael J. Fox Foundation webinar hosted by BioSymetrics. BioSymetrics has developed algorithms and digital biomarkers that can be applied for diagnosis, patient stratification, and treatment response prediction, as well as to accelerate therapeutic development. Its applied AI projects have used large-scale datasets to refine Parkinson's subtypes for precision medicine applications. As Lunai's wholly owned subsidiary, BioSymetrics' Parkinson's initiative spans drug target discovery, validation, and clinical study optimization.
Lunai Bioworks to Execute 10-for-1 Reverse Stock Split
Lunai Bioworks has approved a 10:1 reverse stock split of its issued and outstanding common stock, par value $0.0001 per share to be effective 12:01 a.m. ET on September 30. The common stock will trade on Nasdaq under the symbol "LNAI" following the reverse stock split, with a new CUSIP number of 29350E 203. The company expects its common stock to open for trading on a post-split basis on Nasdaq as of the commencement of trading on September 30. The reverse stock split is intended to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq. The reverse stock split is expected to reduce the number of shares of the company's common stock outstanding on or about September 30 from approximately 231,780,434 shares to approximately 23,178,096 shares. The reverse stock split will not affect the number of authorized shares of common stock.
BioSymetrics and Brigham and Women's Hospital Receive NIH STTR Grant
Lunai Bioworks' BioSymetrics announced the award of a Small Business Technology Transfer grant from the National Institutes of Health. The funding, awarded jointly to BioSymetrics and Brigham and Women's Hospital, will support the development of a novel platform that combines artificial intelligence and in vivo zebrafish screening to accelerate drug discovery for Alcohol Use Disorder, a disease affecting more than 19 million Americans and substantially contributing to the development of both oncologic and neurologic disorders. The grant is a fast-tracked Phase I and Phase II application awarded by the National Institute on Alcohol Abuse and Alcoholism with a total value of $1.85M, contingent upon determination that the Phase I milestones were achieved. The joint program, co-led by Dr. Calum MacRae, Vice Chair for Scientific Innovation at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School, will unite expertise in AI-driven behavioral phenotyping with large-scale drug screening models. The platform will integrate BioSymetrics' proprietary machine learning tools with experimental phenotyping capabilities developed in Dr. MacRae's lab. The project aims to deliver both a scalable discovery engine for AUD as well as novel small molecules that could form the basis for future therapies.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。